site stats

Kiniksa pharmaceuticals stock

Web23 uur geleden · Price To Cash Flow is a widely used stock evaluation measure. ... Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates 02/28/23-10:25AM EST Zacks. Web13 apr. 2024 · Allspring Global Investments Holdings LLC lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) by 890.6% during the …

FDA-Approved Medicines Kiniksa Pharmaceuticals

Web13 apr. 2024 · Allspring Global Investments Holdings LLC lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Rating) by 890.6% during the 4th quarter, according to its most recent disclosure with the SEC.The fund owned 215,119 shares of the company's stock after purchasing an additional 193,404 shares during the … Web5 apr. 2024 · The latest price target for Kiniksa Pharmaceuticals ( NASDAQ: KNSA) was reported by JP Morgan on Thursday, March 9, 2024. The analyst firm set a price target for 20.00 expecting KNSA to rise to... dacc register https://ardorcreativemedia.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Price, News, Quote

Web30 mrt. 2024 · Kiniksa Pharmaceuticals Stock Price Today (NASDAQ: KNSA) Quote, Market Cap, Chart WallStreetZen Kiniksa Pharmaceuticals Ltd Stock Add to … Web13 jan. 2024 · The market capitalization of Kiniksa Pharmaceuticals is $686 522 000. At the same time, the number of shares in circulation is 34 275 000. The company's earnings before interest, taxes and depreciation for last year (called EBITDA) was -127 973 000$. The company has no profit and is unprofitable. WebKiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. dacc registrar

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and …

Category:Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here

Tags:Kiniksa pharmaceuticals stock

Kiniksa pharmaceuticals stock

Ensign Peak Advisors Inc Has $998,000 Stock Position in Kiniksa ...

Web2 dec. 2024 · Kiniksa Pharmaceuticals (NASDAQ:KNSA) is a Massachusetts based biotech that IPO'd in April 2024, raising $152m at $19 per share ... Pharma and Healthcare stocks and share investment tips. WebKiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for …

Kiniksa pharmaceuticals stock

Did you know?

Web30 mrt. 2024 · Kiniksa Pharmaceuticals Ltd is down 4.04% from its previous closing price of $11.15. During the last market session, Kiniksa Pharmaceuticals Ltd’s stock traded … Web31 mrt. 2024 · Kiniksa Pharmaceuticals, Ltd. (KNSA) has been beaten down lately with too much selling pressure. While the stock has lost 13.3% over the past four weeks, there is …

Web28 feb. 2024 · Wall Street predict expect Kiniksa Pharmaceuticals will report losses per share of $0.175 Track Kiniksa Pharmaceuticals stock price in real-time on Markets … Web28 feb. 2024 · Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2024. Do …

WebUS Headquarters. Kiniksa Pharmaceuticals Corp. 100 Hayden Avenue. Lexington, MA 02421 USA. (781) 431-9100. USA California. Kiniksa Pharmaceuticals Corp. 9191 Towne Centre Drive, Suite 330. San Diego, CA 92122. Web6 jan. 2024 · In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report), with a price target of $20.00. The company's shares closed last Thursday at $11.10. According to TipRanks.com, Bayko is a 4-star analyst with an average return of 9.1% and a 45.4% success rate.

Web23 uur geleden · Price To Free Cash Flow is a widely used stock evaluation measure. ... Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates 02/28/23-10:25AM EST Zacks.

Web10 apr. 2024 · Conclusions. Kiniksa Pharmaceuticals Ltd. Class A Common Stock is assigned short-term Ba1 & long-term Ba1 estimated rating. Kiniksa Pharmaceuticals Ltd. Class A Common Stock prediction model is evaluated with Modular Neural Network (Market Volatility Analysis) and Stepwise Regression 1,2,3,4 and it is concluded that the KNSA … dacc swimWebKNSA : 10.97 (+1.95%) Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why Zacks - Mon Nov 7, 2024. Kiniksa Pharmaceuticals, Ltd. … dacc17Web6 apr. 2024 · Every Second Counts! ANNUAL 20. REPORT 21. Dear Fellow Shareholders, The steadfast dedication of our employees, despite another year of pandemic challenges, led Kiniksa to a profoundly transformational year in 2024. We evolved into a commercial-stage company with the successful launch of ARCALYST® (rilonacept) for recurrent … dacc star auditWeb28 feb. 2024 · Kiniksa Pharmaceuticals, Ltd. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $61.88 million for the quarter ended December 2024, surpassing the... dacc respiratory programWeb13 apr. 2024 · Allspring Global Investments Holdings LLC lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) by 890.6% during the 4th quarter, according to its most recent ... dacc staffWeb1 dag geleden · Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Historical Prices & Data - Yahoo Finance U.S. markets open in 6 hours 17 minutes S&P Futures -4.50(-0.11%) … dacc nysWeb9 apr. 2024 · Kiniksa Pharmaceuticals (NASDAQ:KNSA) has had a rough three months with its share price down 26%. ... This then helps them determine if the stock is placed for a bright or bleak future. dacca boots